S&P 500   3,156.56 (+0.48%)
DOW   28,049.65 (+0.50%)
QQQ   205.58 (+0.29%)
FB   197.76 (-2.22%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,753.31 (+0.26%)
CGC   21.05 (+3.95%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
GE   11.38 (+3.74%)
T   38.37 (+0.52%)
F   9.28 (+1.87%)
NFLX   296.57 (-0.79%)
BAC   34.46 (+2.44%)
GILD   67.60 (-0.27%)
DIS   147.62 (+0.02%)
S&P 500   3,156.56 (+0.48%)
DOW   28,049.65 (+0.50%)
QQQ   205.58 (+0.29%)
FB   197.76 (-2.22%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,753.31 (+0.26%)
CGC   21.05 (+3.95%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
GE   11.38 (+3.74%)
T   38.37 (+0.52%)
F   9.28 (+1.87%)
NFLX   296.57 (-0.79%)
BAC   34.46 (+2.44%)
GILD   67.60 (-0.27%)
DIS   147.62 (+0.02%)
S&P 500   3,156.56 (+0.48%)
DOW   28,049.65 (+0.50%)
QQQ   205.58 (+0.29%)
FB   197.76 (-2.22%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,753.31 (+0.26%)
CGC   21.05 (+3.95%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
GE   11.38 (+3.74%)
T   38.37 (+0.52%)
F   9.28 (+1.87%)
NFLX   296.57 (-0.79%)
BAC   34.46 (+2.44%)
GILD   67.60 (-0.27%)
DIS   147.62 (+0.02%)
S&P 500   3,156.56 (+0.48%)
DOW   28,049.65 (+0.50%)
QQQ   205.58 (+0.29%)
FB   197.76 (-2.22%)
GOOGL   1,340.21 (-0.30%)
AMZN   1,753.31 (+0.26%)
CGC   21.05 (+3.95%)
NVDA   221.12 (+1.74%)
MU   50.78 (+3.09%)
GE   11.38 (+3.74%)
T   38.37 (+0.52%)
F   9.28 (+1.87%)
NFLX   296.57 (-0.79%)
BAC   34.46 (+2.44%)
GILD   67.60 (-0.27%)
DIS   147.62 (+0.02%)
Log in

NASDAQ:MRUS - Merus Stock Price, Forecast & News

$17.00
-0.02 (-0.12 %)
(As of 12/12/2019 02:19 PM ET)
Today's Range
$16.96
Now: $17.00
$17.06
50-Day Range
$14.16
MA: $15.89
$18.50
52-Week Range
$11.00
Now: $17.00
$20.95
Volume410 shs
Average Volume69,431 shs
Market Capitalization$397.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.14 million
Book Value$4.77 per share

Profitability

Net Income$-28,660,000.00

Miscellaneous

Employees98
Market Cap$397.97 million
Next Earnings Date4/1/2020 (Estimated)
OptionableNot Optionable

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.


Merus (NASDAQ:MRUS) Frequently Asked Questions

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

When is Merus' next earnings date?

Merus is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Merus.

What price target have analysts set for MRUS?

6 equities research analysts have issued 1-year price objectives for Merus' shares. Their forecasts range from $16.00 to $35.00. On average, they expect Merus' share price to reach $24.00 in the next year. This suggests a possible upside of 41.2% from the stock's current price. View Analyst Price Targets for Merus.

What is the consensus analysts' recommendation for Merus?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Has Merus been receiving favorable news coverage?

Headlines about MRUS stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merus earned a news sentiment score of -3.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Merus.

Are investors shorting Merus?

Merus saw a increase in short interest in November. As of November 15th, there was short interest totalling 377,300 shares, an increase of 34.3% from the October 31st total of 281,000 shares. Based on an average daily trading volume, of 95,500 shares, the days-to-cover ratio is currently 4.0 days. Currently, 2.7% of the company's shares are sold short. View Merus' Current Options Chain.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Who are Merus' key executives?

Merus' management team includes the folowing people:
  • Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.01%) and State of Tennessee Treasury Department (0.01%).

Which institutional investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including State of Tennessee Treasury Department.

Which institutional investors are buying Merus stock?

MRUS stock was acquired by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $17.00.

How big of a company is Merus?

Merus has a market capitalization of $397.97 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.

What is Merus' official website?

The official website for Merus is http://www.merus.nl/.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (NASDAQ MRUS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  482
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel